tiprankstipranks
Shanrong Biotechnology Corp (SRBT)
OTHER OTC:SRBT
Holding SRBT?
Track your performance easily

Shanrong Biotechnology (SRBT) Income Statement

1 Followers

Shanrong Biotechnology Income Statement

Last quarter (Q ), Shanrong Biotechnology's total revenue was $109.65K, an increase of Infinity% from the same quarter last year. In Q, Shanrong Biotechnology's net income was $-4.07M. See Shanrong Biotechnology’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 09Dec 08Jul 08
Total Revenue
$ 1.32M$ 1.32M$ 692.47K-
Cost of Revenue
-$ 0.00$ 0.00-
Gross Profit
$ 1.32M$ 1.32M$ 692.47K-
Operating Expense
$ 6.25M$ 6.13M$ 3.11M$ 33.51K
Operating Income
$ -4.93M$ -4.81M$ -2.41M$ -33.51K
Net Non Operating Interest Income Expense
$ -270.20K$ -270.20K$ -306.72K-
Other Income Expense
$ 533.00$ 533.00$ 787.00$ -6.23K
Pretax Income
$ -5.08M$ -5.08M$ -2.72M-
Tax Provision
-$ 0.00$ 0.00-
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -5.08M$ -5.08M$ -2.72M$ -39.74K
Basic EPS
$ -15.00$ -16.00$ -9.00$ -1.00
Diluted EPS
$ -15.00$ -16.00$ -9.00$ -1.00
Basic Average Shares
$ 1.29M$ 323.01K$ 317.96K$ 42.56K
Diluted Average Shares
$ 1.37M$ 343.72K$ 317.96K$ 42.56K
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 6.25M$ 6.13M$ 3.11M$ 33.51K
Net Income From Continuing And Discontinued Operation
$ -5.08M$ -5.08M$ -2.72M$ -39.74K
Normalized Income
$ -5.08M$ -5.08M$ -2.72M$ -33.51K
Interest Expense
$ 270.20K$ 270.20K$ 306.72K-
EBIT
$ -4.81M$ -4.81M$ -2.41M$ -33.51K
EBITDA
$ -4.69M$ -4.77M$ -2.38M$ -33.51K
Currency in USD

Shanrong Biotechnology Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis